Showing 2241-2250 of 2494 results for "".
- TearLab Announces Adam Szaronos as President and CEO, and Jim Mazzo as Executive Chairman of the Boardhttps://modernod.com/news/tearlab-announces-adam-szaronos-as-president-and-ceo-and-jim-mazzo-as-executive-chairman-of-the-board/2480506/TearLab announced that Adam Szaronos has been appointed President and Chief Executive Officer by the company's Board of Dir
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&
- Moderna, Regeneron Warn About the Effectiveness of COVID-19 Drugs, Vaccines Against the Omicron Varianthttps://modernod.com/news/moderna-regeneron-warn-about-the-effectiveness-of-covid-19-drugs-vaccines-against-the-omicron-variant/2480484/As the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current offerings may not be effective against the variant, according to a FiercePharma
- Oyster Point Pharma Expands Executive Leadership Team to Support Commercialization of Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-expansion-of-executive-leadership-team-to-support-commercialization-of-tyrvaya-nasal-spray/2480475/Oyster Point Pharma announced the promotion of Barry Rosenfeld, JD, as General Counsel; and Raegan A. McClain, JD, LLM, CCEP, as Chief Compliance Officer, both of whom will join the executive leadership team. “We are thrilled to expand our executive
- Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europehttps://modernod.com/news/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe/2480459/Nicox SA announced that patent EP 3,769,753, expiring in 2040 and covering the company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office (EPO). The patent covers ophthalmic suspensions comprising a specific form of fluticas
- Spherix Global Insights Introduces Ophthalmology to Suite of Independent Market Research and Intelligence Serviceshttps://modernod.com/news/spherix-global-insights-introduces-ophthalmology-to-suite-of-independent-market-research-and-intelligence-services/2480450/Spherix Global Insights, a market research firm providing independent coverage of select specialty markets, officially cut the ribbon on their ophthalmology franchise. Spherix derives actionable insights from its frequent, commercially-focused, primary market research, which i
- Alcon Inaugurates Company’s Largest European Eye Health Education and Training Center in Barcelonahttps://modernod.com/news/alcon-inaugurates-companys-largest-european-eye-health-education-and-training-centre-in-barcelona/2480404/Alcon officially opened the new Alcon Experience Center (AEC) in Barcelona, one of Europe's largest eye health education and training facilities, offering eye care professionals the opportunity to learn and gain hands-on experience with the latest innovations in ophthalmology and optometry. T
- EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeuticshttps://modernod.com/news/eyegate-pharmaceuticals-closes-acquisition-of-bayon-therapeutics/2480376/EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’
- Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDAhttps://modernod.com/news/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda/2480375/In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device com
- Opus Genetics Announces Two Leadership Appointmentshttps://modernod.com/news/opus-genetics-announces-two-leadership-appointments/2480367/Opus Genetics announced two key appointments to its founding executive team. Ash Jayagopal, PhD, has joined the company as Chief Scientific Officer (CSO); and Joe Schachle has joined as Chief Operating Officer (COO). “We were thrilled to launch Opus last month to advance an A